Table 1.

Participants’ Demographic and Clinical Characteristics (N=160)

Age, m (SD)
Years	9.31	(2.20)
Gender, n (%)
Male	126	(78.75)
Female	34	(21.25)
Race or Ethnic Group, n (%)
White	94	(58.75)
African-American	25	(15.63)
Hispanic	31	(19.38)
Other or mixed heritage	10	(6.25)
Diagnoses Comorbid with ADHD, n (%)
Oppositional defiant disorder	143	89.38
Conduct disorder	17	10.63
Anxiety disorder	39	24.53
Mood disorder	18	11.32
Optimized Stimulant Monotherapy Regimen, n (%)
Stimulant Preparation
Methylphenidate, triphasic release	100	62.50
Methylphenidate, biphasic release	16	10.00
Mixed amphetamine salts, extended release	38	23.75
Other	6	3.75
Total daily dose in MPH equivalent, m (SD)
Complete sample	43.07	15.63
Aggression-remitted group	42.02	16.06
Aggression-refractory group	44.61	16.58
Days from baseline assessment to final stimulant monotherapy endpoint assessment, m (SD)
Complete sample	70.22	37.47
Aggression-remitted group	67.90	35.73
Aggression-refractory group	72.66	39.30

Note: ADHD = attention-deficit/hyperactivity disorder; MPH = methylphenidate